정부/공공기관
임상시험센터
CRO
분석CRO/센트럴랩
유관기관/협회
정보서비스
해외 유관 기관
* CRO 게재 기준: CRO자율등록 기관
ClinicalTrials.gov에 등록된 정보를 기준으로 코로나-19(COVID-19) 관련 글로벌 임상시험 현황을 제공합니다.
전체 2550건이 검색되었습니다.
| No. | Status | Study Title | Conditions | Interventions | Phase | Sponsor/Collaborators | Funder Type | Number Enrolled | Sex | Age | Locations |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 891 | Active, not recruiting | Phase I/II Study of COVID-19 DNA Vaccine (AG0302-COVID19 High-dose) | COVID-19 Lower Respiratory Infection | Biological: AG0302-COVID19 for Intramuscular Injection Biological: AG0302-COVID19 for Intramuscular Injection Biological: AG0302-COVID19 for Intramuscular Injection Biological: AG0302-COVID19 for Intradermal Injection Biological: AG0302-COVID19 for Intradermal Injection |
Phase 2 | AnGes, Inc., Japan Agency for Medical Research and Development | INDUSTRY | 400 | All | 18 Years | IUHW Narita Hospital, Narita, Chiba, Japan Medical Corporation Heishinkai OCROM Clinic, Suita, Osaka, Japan Medical Corporation Heishinkai ToCROM Clinic, Shinjuku-ku, Tokyo, Japan Medical Corporation Shinanokai Shinanozaka Clinic, Shinjuku-ku, Tokyo, Japan Sekino Clinical Pharmacology Clinic, Toshima-ku, Tokyo, Japan Medical Corporation Heishinkai OPHAC Hospital, Osaka, Japan |
| 890 | Not yet recruiting | Phase I/II Trial of Povidone-iodine (PVP-I) Nasal Swab For Preventing COVID-19 Spread in Healthy Subjects | Povidone Iodine Adverse Reaction | Drug: Povidine iodine nasal swabs | Phase 2 | Brigham and Women's Hospital, 3M | OTHER | 50 | All | 18 Years ~ 70 Years | |
| 889 | Active, not recruiting | Phase II / III Study of COVID-19 DNA Vaccine (AG0302-COVID19) | COVID-19 | Biological: Group A (AG0302-COVID19) Biological: Group A (Placebo) Biological: Group B (AG0302-COVID19) Biological: Group B (Placebo) |
Phase 3 | AnGes, Inc., Japan Agency for Medical Research and Development | INDUSTRY | 500 | All | 18 Years | UHW Narita Hospital, Narita, Chiba, Japan Medical Corporation Heishinkai OCROM Clinic, Suita, Osaka, Japan Medical Corporation Tsurukamekai Shinjuku Tsurukame C linic, Shibuya-ku, Tokyo, Japan Medical Corporation Heishinkai ToCROM Clinic, Shinjuku-ku, Tokyo, Japan Medical Corporation Shinanokai Shinanozaka Clinic, Shinjuku-ku, Tokyo, Japan Sekino Clinical Pharmacology Clinic, Toshima-ku, Tokyo, Japan NISHI-UMEDA Clinic for Asian Medical Collaboration, Osaka, Japan Medical Corporation Heishinkai OPHAC Hospital, Osaka, Japan |
| 888 | Active, not recruiting | Phase II Clinical Trial of CinnaGen COVID-19 Vaccine (SpikoGen) | Covid19 | Biological: SARS-CoV-2 recombinant spike protein + Advax-SM adjuvant Biological: Saline placebo |
Phase 2 | Cinnagen, Vaxine Pty Ltd | INDUSTRY | 400 | All | 18 Years | Espinas Palace Hotel, Tehran, Iran, Islamic Republic of |
| 887 | Recruiting | Phase II Clinical Trial of Recombinant SARS-CoV-2 Spike Protein Vaccine (CHO Cell) | COVID-19 | Biological: 202-CoV low adjuvant dose Biological: 202-CoV low antigen dose Biological: 202-CoV standard dose Biological: Placebo |
Phase 2 | Shanghai Zerun Biotechnology Co.,Ltd, Walvax Biotechnology Co., Ltd. | INDUSTRY | 1056 | All | 18 Years | Xiangcheng Center for Disease Control and Prevention, Xuchang, China |
| 886 | Withdrawn | Phase II RCT to Assess Efficacy of Intravenous Administration of Oxytocin in Patients Affected by COVID-19 | SARS-CoV 2 | Drug: Oxytocin Drug: Standard of Care |
Phase 2 | Azienda Ospedaliero-Universitaria di Parma, University of Parma | OTHER | 0 | All | 18 Years | CNRS, Lyon, France Azienda Ospedaliero Universitaria di Parma, Parma, PR, Italy Ospedale San Francesco, Nuoro, Italy |
| 885 | Recruiting | Phase II/III Study of AZD2816, for the Prevention of COVID-19 in Adults | SARS-CoV-2 | Biological: AZD1222 Biological: AZD2816 |
Phase 3 | AstraZeneca | INDUSTRY | 2849 | All | 18 Years ~ 115 Years | Research Site, Brasilia, Brazil Research Site, Curitiba, Brazil Research Site, Natal, Brazil Research Site, Natal, Brazil Research Site, Porto Alegre, Brazil Research Site, Salvador, Brazil Research Site, Sao Paulo, Brazil Research Site, Krakow, Poland Research Site, Lublin, Poland Research Site, O?wi?cim, Poland Research Site, Puławy, Poland Research Site, Skorzewo, Poland Research Site, Trzebnica, Poland Research Site, Zamosc, Poland Research Site, Bloemfontein, South Africa Research Site, Cape Town, South Africa Research Site, Johannesburg, South Africa Research Site, Johannesburg, South Africa Research Site, Johannesburg, South Africa Research Site, Somerset West, South Africa Research Site, Birmingham, United Kingdom Research Site, Bournemouth, United Kingdom Research Site, Bristol, United Kingdom Research Site, Bristol, United Kingdom Research Site, Dundee, United Kingdom Research Site, Edinburgh, United Kingdom Research Site, Harrow, United Kingdom Research Site, Hull, United Kingdom Research Site, London, United Kingdom Research Site, London, United Kingdom Research Site, London, United Kingdom Research Site, London, United Kingdom Research Site, Manchester, United Kingdom Research Site, Newcastle-upon-Tyne, United Kingdom Research Site, Nottingham, United Kingdom Research Site, Oxford, United Kingdom Research Site, Plymouth, United Kingdom Research Site, Portsmouth, United Kingdom Research Site, Sheffield, United Kingdom Research Site, Truro, United Kingdom |